ARTICLE | Clinical News
Arzerra regulatory update
December 14, 2016 11:00 PM UTC
Genmab said the European Commission approved an expanded label for Arzerra ofatumumab from Novartis to include treatment of relapsed chronic lymphocytic leukemia (CLL) in combination with fludarabine ...
BCIQ Target Profiles